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Abstract
Migration of new neuroprogenitor cells (NPCs) from the subventricular zone (SVZ) plays an important role in
neurorepair after injury. Previous studies have shown that brain derived neurotrophic factor (BDNF) enhances the
migration of NPCs from SVZ explants in neonatal mice in vitro. The purpose of this study was to identify the role of
BDNF in SVZ cells using AAV-BDNF in an animal model of stroke. BDNF protein production after AAV‐BDNF
infection was verified in primary neuronal culture. AAV-BDNF or AAV-RFP was injected into the left SVZ region of
adult rats at 14 days prior to right middle cerebral artery occlusion (MCAo). SVZ tissues were collected from the brain
and placed in Metrigel cultures 1 day after MCAo. Treatment with AAV-BDNF significantly increased the migration of
SVZ cells in the stroke brain in vitro. In another set of animals, AAV-GFP was co-injected with AAV-BDNF or AAV-
RFP to label cells in left SVZ prior to right MCAo. Local administration of AAV-BDNF significantly enhanced recovery
of locomotor function and migration of GFP-positive cells from the SVZ toward the lesioned hemisphere in stroke
rats. Our data suggest that focal administration of AAV-BDNF to the SVZ increases behavioral recovery post stroke,
possibly through the enhancement of migration of cells from SVZ in stroke animals. Regional manipulation of BDNF
expression through AAV may be a novel approach for neurorepair in stroke brains.
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Introduction
Experimental data has supported the idea that brain derived
neurotrophic factor (BDNF) has beneficial effects in animal
models of stroke. For example, treatment with BDNF reduces
the size of brain infarction when given prior to middle cerebral
artery occlusion (MCAo) in rodents [1]. Similarly,
intracerebroventricular administration of adeno-associated
virus (AAV) carrying the BDNF gene reduces brain infarction
[2]. Pretreatment with BDNF reduces ischemia -mediated
changes in BAX [3]and TUNEL labeling [4], suggesting the
protection from BDNF is mediated through the inhibition of
apoptosis.
De novo neurogenesis has been found in the subventricular
zone (SVZ) of adult mammalian brain. Increasing apoptosis in
SVZ cells was found in BDNF deficient mutant mice [5]. TrkB is
one of the most prominent neurotrophin receptors, in truncated
isoform, in the SVZ of non-stroke mice [6]. Activation of pan-
neurotrophin receptor p75 by BDNF regulates the
neurogenesis in adult SVZ [7]. In contrast, BDNF, delivered
intraventricularly, did not increase the SVZ neurogenesis in
non-lesioned rodents [5]. In the intact animal, neuroprogenitor
cells (NPCs) originating in the SVZ mainly migrated to the
olfactory bulb. The migration of NPCs from the SVZ toward
olfactory bulb is enhanced by BDNF [8,9]. These data suggest
that migration and/or neurogenesis of NPCs in SVZ can be
modulated by BDNF in non-lesioned adult brain [10,11].
We have used a rat distal MCAo model to characterize time-
dependent proliferation and migration of NPC in the SVZ [13].
In contrast to non-stroke animals, NPCs from the SVZ mainly
migrate toward the lesioned brain region in stroke animals.
Manipulation of the survival or migration of NPCs in SVZ alters
behavioral function in the stroke animals [12,13]. The role of
BDNF in NPCs after stroke is still not fully understood. Indirect
evidence supports that BDNF has neuroreparative effects via
SVZ in stroke animals. For example, intravenous administration
of BDNF stimulated recruitment of NPCs migrate to the
lesioned striatum after stroke [14]. Intraventricular infusion of
BDNF antisense oligonucleotides blocked the expression of
BDNF mRNA and attenuated skilled reaching recovery after
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stroke [15]. We recently demonstrated that repeated intranasal
delivery of cocaine- and amphetamine-regulated transcript
(CART) increased BDNF expression in SVZ and enhanced
behavioral recovery after stroke [12]. CART enhanced the
migration of SVZ explant cells, which was antagonized by
BDNF blocking antibody [12]. Similarly, Chen et al reported that
atorvastatin induced SVZ explant cell migration through BDNF
upregulation and improved neurological function in stroke
animals [16]. A recent study showed that bath application of
BDNF promotes cell displacement in acute ischemic brain
slices [17]. These indirect evidences support that BDNF may
enhance the migration of SVZ cells in stroke brains. It is still not
clear if increasing BDNF expression locally in SVZ enhances
the cell migration and functional recovery in the ischemic brain.
In this study, we demonstrated a neuroregenerative effect of
BDNF after stroke. We found that local overexpression of
BDNF expression in the SVZ by AAV-BDNF enhanced
migration of SVZ cells toward the lesioned hemisphere and
induced recovery of locomotor function in stroke rats.
Materials and Methods
Animals and MCAo
Adult male Sprague-Dawley rats, purchased from Charles
River Laboratories Inc., were housed in an enriched
environment by providing a toy (nylabone) or crinkle paper in
their home cages with a 12 hour dark (6pm to 6 am) and 12
hour light (6 am to 6 pm) cycle. This study was carried out in
strict accordance with the recommendations in the Guide for
the Care and Use of Laboratory Animals of the National
Institutes of Health. The protocol was approved by the
Committee on the Ethics of Animal Experiments of the National
Institutes of Health. All surgery was performed under
anesthesia, and all efforts were made to minimize suffering.
Rats were anesthetized with chloral hydrate (0.4 g/kg, i.p.). The
right MCA was ligated with a 10-O suture and common carotids
were clamped bilaterally by nontraumatic arterial clips to
generate focal infarction in the cerebral cortex. The ligature and
clips were removed after 90-min ischemia to allow reperfusion
as previously described [12,13]. Core body temperature was
maintained at 37 °C. The averaged size of lesion was 190-200
mm3 in the right cerebral cortex, as determined by T2WI as
described previously [12,18]. No animal died during surgery or
during post-stroke drug treatment.
AAV Production and In vitro characterization
The construction of dsAAV-GFP [19] and dsAAV-RFP [20]
dsAAV-RFP packaging plasmids is are based on AAV serotype
2 genome. To generate dsAAV-BDNF, GFP was replaced with
the human BDNF cDNA. Viral stocks were prepared using the
triple-transfection method with modifications [21,22]. Briefly,
twenty 15 cm dishes containing HEK293 cells at 85–95%
confluency were transfected by the CaCl2 method with pHelper
(Stratagene, La Jolla, CA), pdsAAV-GFP or pdsAAV-BDNF
and pXR1 aka pXX12, a plasmid containing the rep/cap genes
for serotype 1. Plasmids used for packaging AAV were
generously provided by Dr. Xiao Xiao (UNC, Chapel Hill, NC).
Approximately 48 hours post-transfection, cells were
harvested, lysed by freeze/thaw, and purified by centrifugation
on a CsCl gradient. Final samples were dialyzed in PBS,
aliquoted and stored at −80°C until use. All vectors were titered
by quantitative PCR using GFP CMV promoter as the target
sequence.
Rat primary cortical neuron cultures were prepared as
described previously [22] and transduced with 11 µl of AAV-
BDNF in 1 ml media. Two days later, media was collected and
60 µl was analyzed for BDNF using an Emax ImmunoAssay Kit
(Promega, Madison, WI). The secreted BDNF was calculated
from a standard curve of recombinant human BDNF protein
provide with kit.
Unilateral AAV injection into SVZ
For the in vitro metrigel study, AAV-BDNF or AAV-RFP (1 µl,
5x109 viral genomes/µl) was stereotactically delivered at a
speed of 0.5 µl/min into left SVZ (AP 0.12 mm, ML 2.1 mm, DV
3.5 mm to bregma). For the in vivo histological study, AAV-
GFP (1 µl, 5x109 viral genomes/µl) was co-administered with
AAV-BDNF or AAV-RFP (1 µl, 5x109 viral genomes/µl) to the
left SVZ (total volume for each site = 2 µl).
Triphenyltetrazolium chloride (TTC) staining
AAV-BDNF or AAV-RFP was injected into the left SVZ region
of adult rats at 14 days prior to right MCAo surgery. Two days
after reperfusion rats were decapitated. The brains were
removed and sliced into 2.0-mm-thick sections. The brain
slices were incubated in a 2% TTC solution (Sigma, St. Louis)
for 15 min at room temperature and then transferred into a 4%
paraformaldehyde solution for fixation. The area of infarction in
each slice was measured with a digital scanner and Imagetools
programs (University of Texas Health Sciences Center). The
volume of infarction in each animal was obtained from the
product of average slice thickness (2 mm) and sum of infarction
areas in all brain slices examined.
Locomotor Behavior
Animals were individually placed in 42x42x31 cm behavioral
chambers for 60 minutes (Accuscan activity monitor,
Columbus, OH). The monitor contained 16 horizontal and 8
vertical infrared sensors spaced 2.5 cm apart. Locomotor
activity was calculated using the number of beams broken by
the animals after placement in the chamber. Four parameters
were measured.
Vertical activity (VACTV): The total number of beam
interruptions that occurred in the vertical sensor. Horizontal
activity (HACTV): the total number of beam interruptions that
occurred in the horizontal sensor. Total distance travelled
(TOTDIST): the distance traveled in centimeters. Movement
time (MOVTIME): The amount of time, in seconds, the animals
was in ambulation.
Histology
Animals were anesthetized with chloral hydrate (400 mg/kg
i.p.) and perfused transcardially with saline followed by 4%
paraformaldehyde (PFA) in phosphate buffer (PB; 0.1 M; pH
7.2). The brains were dissected, post-fixed in PFA for 18 - 20
Targeted Overexpression of BDNF in SVZ for Repair
PLOS ONE | www.plosone.org 2 December 2013 | Volume 8 | Issue 12 | e81750
hours, and transferred to 18% sucrose in 0.1 M PB for at least
16 hours. Serial sections of the entire brain were cut at 25 µm
thickness on a cryostat. Histological images were acquired
using a QImaging Retiga EXi camera and Nikon 80i. GFP
fluorescence was measured as previously described [12].
SVZ explant culture
SVZ explant cultures were prepared from stroke rats. AAV-
BDNF or AAV-RFP was injected into the SVZ region of adult
rats at 14 days prior to MCAo surgery. SVZ tissues were
collected 1 day after 90-min MCAo. SVZ explants were
cultured within Matrigel (BD Biosciences) in Neurobasal
medium containing 2% B27 supplement (Invitrogen). The
distance of SVZ cell migration was examined from days 2-8
after culture [12].
Statistical analysis
Values are means ± s.e.m. Unpaired t-test, 2-way ANOVA,
and post-hoc Newman-Keuls test were used for statistical
analysis. A statistically significant difference was defined as p <
0.05.
Results
(A) AAV-BDNF infection enhances BDNF production in
primary cortical neuronal culture.
Rat primary cortical neurons were transduced with AAV-
BDNF or vehicle. Media was collected for BDNF protein assay
2 days later. The production of BDNF protein was determined
by ELISA. AAV-BDNF treatment significantly increased BDNF
protein level in the media (Figure 1C, p<0.0001, t test).
(B) AAV-BDNF infection enhances migration of SVZ explant
cells from stroke rats.
Cell migration was examined from 144 SVZ explants in vitro.
AAV-BDNF or AAV-RFP was administrated unilaterally into the
left SVZ. Bilateral SVZ explants were harvested and then
placed in Matrigel culture 1 day after right MCAo. The distance
of SVZ cell migration from the explants was examined under
the microscope from days 1-8 after culture. There was minimal
migration on DIV2 (Fig 1A). Using a three way ANOVA, we
found that AAV-BDNF significantly enhanced cell migration
(F=146.450, p<0.001, Figure 1A, 1B). Post-hoc Newmann
Keuls test analysis indicates that treatment with AAV-BDNF,
compared to AAV-RFP, enhanced the distance of cell migration
from the Left SVZ on DIV 6, 7, and 8 (p<0.001, Figure 1B).
These data suggest that local AAV-BDNF infection enhances
migration of cells from SVZ explants in vitro.
(C) Pre-stroke administration of AAV-BDNF to the
contralateral SVZ did not alter the size of infarction.
AAV-BDNF or AAV-RFP was administered locally to the left
SVZ at 14 days prior to the right MCAo in 10 rats. Cerebral
infarction was examined by TTC staining 2 days after MCAo.
We found that pretreatment with AAV-BDNF did not
significantly alter the size of infarction (AAV-BDNF 128.0 ± 26.9
mm3 vs AAV-RFP: 112.4 ± 18.3 mm3, p=0.645, t test).
(D) Behavioral recovery induced by AAV-BDNF treatment in
stroke rats.
AAV-BDNF or AAV-RFP was given locally to the left SVZ 14
days prior to MCAo in 16 rats. Animals were placed individually
into the activity chamber to monitor 4-hour horizontal activity,
total distance travelled, movement time and vertical activity 1-
day prior to and 3, 6, and 11 days after MCAo or sham surgery.
Administration of AAV-BDNF did not alter locomotor activity
prior to MCAo (Figure 2) or after sham surgery (data not
shown). Animals receiving AAV-BDNF demonstrated
behavioral improvement post-stroke. Horizontal activity, total
distance travelled, movement time, and vertical activity were
significantly increased after MCAo in AAV-BDNF, compared to
AAV-RFP, -treated rats (Figure 2, p<0.05, 2-way ANOVA;
p<0.05, post-hoc Newman-Keuls test). These results
demonstrate that focal administration of AAV-BDNF in non-
lesioned side SVZ is effective in improving the functional
outcome in stroke rats.
(E) AAV-BDNF increases migration of SVZ cells toward the
lesioned side hemisphere in the stroke rats.
A total of 16 rats were treated with AAV-BDNF or AAV-RFP
in the non-lesioned side (Left) SVZ at 7 days prior to MCAo or
sham surgery. SVZ cells were also labeled with GFP by co-
administration of AAV-GFP. Brain tissues were harvested 12
days after MCAo. GFP(+) cells migrated bilaterally from the
injection site, but mainly toward to the lesioned hemisphere in
stroke animals (Figure 3). Limited cell migration along the
corpus callosum was found in non-stroke animals. Treatment
with AAV-BDNF enhanced GFP(+) cell migration from the
contralateral SVZ toward the ischemic cortex only in stroke
animals (Figure 3). The rate of cell migration (µm per day) was
calculated by averaging the distance of GFP (+) cells travelling
from the contralateral SVZ toward ischemic hemisphere after
MCAo treatment (i.e. 12 days). AAV-BDNF infection
significantly increased the rate of cell migration in stroke
animals (Figure 4, p=0.011, t test).
Discussion
Overexpression of BDNF via AAV has been shown to induce
neural protection and regeneration in various lesion models.
AAV-BDNF infection increased the neural and progenitor cell
survival in striatum in the quinolinic acid rodent model of
Huntington’s disease [23,24]. Pretreatment with AAV-BDNF,
given i.c.v., reduced the size of brain infarction in the focal
ischemic model [2]. In this study, AAV-BDNF was administered
locally to the non-lesioned side SVZ, a region that is actively
involved in neural repair after stroke. We demonstrated that
AAV-BDNF delivered to the SVZ contralateral to MCAo did not
alter the size of infarction, however, enhanced endogenous
NPC migration from SVZ and improved functional recovery in
stroke animals.
The migration of endogenous NPCs from SVZ of stroke rats
was examined in culture and in vivo. Using the in vitro Metrigel
culture technique, we demonstrated an enhanced cell migration
from SVZ explants receiving AAV-BDNF. There was no change
in migration from the SVZ contralateral to viral injection,
suggesting that the trophic response is limited to the site of
infection. In the in vivo study, we administered AAV-BDNF to
the SVZ region, contralateral to the MCAo. We found that
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migration of labeled SVZ cells in the corpus callosum towards
the ischemic hemisphere was significantly enhanced by AAV-
BDNF in stroke animals. In contrast, there was limited cell
migration in the corpus callosum in non-stroke rats, treated with
either AAV-BDNF or AAV-RFP. We also measured horizontal
and vertical activity in stroke rats. A significant recovery of
behavioral function was found in animals receiving AAV-BDNF.
These data suggest that local injection of AAV-BDNF facilitates
the migration of SVZ cells to the contralateral hemisphere in
stroke rats.
BDNF has been shown to enhance migration of NPCs in
SVZ in non-lesioned animals; the migration is mainly toward
the olfactory bulbs [9–11]. Limited reports indirectly support the
effect of BDNF on SVZ cell migration in stroke animals. For
example, systemic administration of BDNF enhanced
recruitment of NPCs into the ipsilateral striatum after stroke
[14]. Administration of drugs, such as CART or atorvastatin,
increased the expression of BDNF and enhanced migration of
SVZ cells [12,25]. However, in these studies, systemically
applied BDNF or its agonists can interact with multiple
Figure 1.  Treatment with AAV-BDNF enhances cell migration from SVZ explants derived from stroke brains.  Adult rats
were infected with AAV-BDNF or AAV-RFP unilaterally into the left (L) SVZ 2 weeks prior to right (R) MCAo. Bilateral SVZ tissues
were harvested one day after MCAo and were cultured separately in Matrogel. The migration of SVZ cells from the explants was
examined microscopically from days 1-8 after culture. (A) Representative images of SVZ explants from stroke animals pretreated
with AAV-RFP (upper panels) or AAV-BDNF (lower panels). AAV-BDNF treatment increased cell migration from the left SVZ
explants (AAV-BDNF-L) on DIV 8. There was minimal migration on DIV2. Calibration= 500 µm. (B)AAV-BDNF, compared to AAV-
RFP, enhanced cell migration from the SVZ explants on DIV8. AAV-BDNF did not alter the migration of SVZ cells from the
hemispheres contralateral to the viral injection (R). *p<0.001, 3- Way ANOVA + post-hoc Newman Keuls test. (C) AAV-BDNF
increased BDNF secretion in primary cortical neurons. Rat primary cortical neurons (DIV6) were mock transduced or transduced
with AAV-BDNF. Media was collected 2 days after transduction and analyzed for BDNF. Only cells transduced with AAV-BDNF
showed significant increases above background (p<0.0001, t-test).
doi: 10.1371/journal.pone.0081750.g001
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anatomical sites. It is not clear if the improvement of cell
migration is mediated through an action in SVZ or the target
lesioned sites [1]. In current study, overexpression of BDNF
was achieved locally in the SVZ via recombinant AAV delivery.
Our data support a trophic response with BDNF in the SVZ to
enhance the migration of these cells toward the lesioned target.
Cerebral ischemia can activate proliferation of NPCs for
endogenous repair. However, most of these cells die and do
not migrate to the lesioned area [13]. We previously
demonstrated that enhancing survival of the endogenous
neural progenitor cells (NPCs) in SVZ by a p53 inhibitor,
pifithrin-α, improved functional recovery in stroke animals [13].
In this study, we demonstrated local AAV-BDNF administration
enhanced the migration of the SVZ cells in stroke rats. Future
studies will examine the additive/ synergisitic effect of
Figure 2.  Local treatment with AAV-BDNF improved locomotor behavior in stroke rats.  (A-D) Abscissa indicates that rats
were subjected to a 90- min MCAo surgery on day 0. AAV-RFP or AAV-BDNF was administered locally to left SVZ to animals 14
days prior to MCAo. Animals were placed individually into the activity chamber to monitor 4-hour locomotor behavior. Behavioral
measurements were carried out in automated activity chambers for 4 hours at 1 day before, 3, 6, and 11 days after MCAo. No
difference was found before MCAo on day -1. Rats that received AAV-BDNF treatment show enhanced recovery in motor function
demonstrated by significant increases in (A) total distance traveled, (B) horizontal activity, (C) movement time, and (D) vertical
activity compared to the control stroke group receiving AAV-RFP (p<0.05, 2-way ANOVA; * p<0.05, post-hoc Newman-Keuls test).
doi: 10.1371/journal.pone.0081750.g002
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Figure 3.  Increases in BDNF expression in SVZ enhance cell migration in stroke rats.  Local administration of AAV-BDNF in
the Left SVZ enhanced cell migration from SVZ toward the ischemic cortex (Right) in stroke animals. (A-D) Animals were treated
with AAV-BDNF/AAV-GFP or AAV-RFP/AAV-GFP in the contralateral (Left) SVZ 14 days prior to (A,B) MCAo or (C,D) sham
surgery. Pretreatment with (B) AAV-BDNF, compared to (A) AAV-RFP, increased migration of GFP(+) cells from SVZ, along the
corpus callosum, toward lesioned side hemisphere (Right) on day 12 post-stroke. (C,D) Limited cell migration was found in the
corpus callosum of non-stroke rats. CC: corpus callosum; LV: Left ventricle; Str: striatum .
doi: 10.1371/journal.pone.0081750.g003
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combined treatment for enhancing the survival and migration in
stroke animals.
Figure 4.  Rate of cell migration was significantly
increased in stroke animals treated with AAV-BDNF.  The
rate of cell migration (µm per day) was calculated by averaging
the distance of GFP (+) cells travelling from the Left SVZ
toward the ischemic hemisphere (Right) after right MCAo
treatment in 12 days. *p<0.05, t test.
doi: 10.1371/journal.pone.0081750.g004
A recent report indicated that activation of AMPA receptors
post-stroke enhances behavioral recovery through BDNF
signaling in stroke mice [26]. Similarly, systemic administration
of the N-methyl-D-aspartate (NMDA) receptor blocker MK-801
suppressed neurogenesis in hippocampus after MCAo in rats
[27]. On the other hand, local overexpression of glutamate
transport-1 (GLU1) in the ischemic cortex reduced brain
damages in stroke rats [28]. These data support two opposite
reactions of excitatory amino acids in stroke. Activation of
glutamate receptors enhances neurodegeneration in the
ischemic region, while it induces neuroregeneration through
BDNF in non-injured regions. These conflicting responses may
partially underlie the failure of using GluR antagonists in clinical
trials in stroke patients [29]. A better approach would be
reducing glutamate concentration locally in the lesioned area,
for example targeted overexpression of GLT-1 in the ischemic
brain region as we previously described [28], and boosted
endogenous neurorepair in non-lesioned region by enhancing
the BDNF expression at the SVZ as presented in this study.
Conclusion
We demonstrated that focal delivery of AAV-BDNF to the
non-lesioned side SVZ increased migration of NPCs in SVZ
and improved behavioral function in stroke animals. Our results
may provide a new treatment target at the non-lesioned side
SVZ for stroke patients through gene or recombinant protein
therapy.
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